Our long-range goal is to understand the roles of membrane-bound and cytosolic proteins that direct the sorting of cargo into COPII vesicles budding from endoplasmic reticulum (ER) of mammalian cells. The mechanism by which cargo is selected and concentrated during export is unknown. To address this goal, we will focus on the central role of the Sar1 GTPase and its upstream and downstream effectors in cargo selection.
Aim I. Molecular basis for Sar1 activation leading to transitional element formation. We will examine the mechanism by which Sarl directs the assembly of export sites through interaction with the mammalian Sec12 guanine nucleotide exchange factor (GEF) to generate tubular elements that form using a KIF-dependent process.
Specific Aim II. Biochemical basis for cargo selection. We will explore the hypothesis that novel components of pre budding complexes are part of a protein machine that coordinates cargo selection with other aspects of ER function to select cargo into COPII vesicles. We will address the molecular basis for cargo recognition, Sec23/24 recruitment and coat polymerization by Sar1, and generate transgenic mouse models to pursue the unique functions of mammalian Sec24 (A-D) isoforms.
Specific Aim I ll. Vesicle maturation. We will explore the basis for coordination of cargo recruitment with the recruitment of molecular tethers and targeting/fusion determinants. We will determine the structural organization of the tether p115 using x-ray crystallography. We will explore the contribution of Sec13/31 to the completion of budding and fission of COPII vesicles from the ER through biochemical, molecular and structural analyses, allowing us to test different models for COPII coat polymerization. The proposed studies should allow us to develop significant mechanistic insight into the crucial early events in the secretory pathway that control the flow of nearly one-third of genome into the cell.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Research Project (R01)
Project #
5R01GM042336-17
Application #
7103548
Study Section
Cell Development and Function Integrated Review Group (CDF)
Program Officer
Shapiro, Bert I
Project Start
1990-08-01
Project End
2007-12-31
Budget Start
2006-08-01
Budget End
2007-12-31
Support Year
17
Fiscal Year
2006
Total Cost
$412,401
Indirect Cost
Name
Scripps Research Institute
Department
Type
DUNS #
781613492
City
La Jolla
State
CA
Country
United States
Zip Code
92037
Amaral, Margarida D; Balch, William E (2015) Hallmarks of therapeutic management of the cystic fibrosis functional landscape. J Cyst Fibros 14:687-99
Roth, Daniela Martino; Hutt, Darren M; Tong, Jiansong et al. (2014) Modulation of the maladaptive stress response to manage diseases of protein folding. PLoS Biol 12:e1001998
Hutt, Darren M; Balch, William E (2013) Expanding proteostasis by membrane trafficking networks. Cold Spring Harb Perspect Med 3:1-21
Powers, Evan T; Balch, William E (2013) Diversity in the origins of proteostasis networks--a driver for protein function in evolution. Nat Rev Mol Cell Biol 14:237-48
Pottekat, Anita; Becker, Scott; Spencer, Kathryn R et al. (2013) Insulin biosynthetic interaction network component, TMEM24, facilitates insulin reserve pool release. Cell Rep 4:921-30
Hutt, Darren M; Balch, William E (2013) Expanding proteostasis by membrane trafficking networks. Cold Spring Harb Perspect Biol 5:
Coppinger, Judith A; Hutt, Darren M; Razvi, Abbas et al. (2012) A chaperone trap contributes to the onset of cystic fibrosis. PLoS One 7:e37682
Hutt, Darren M; Roth, Daniela Martino; Chalfant, Monica A et al. (2012) FK506 binding protein 8 peptidylprolyl isomerase activity manages a late stage of cystic fibrosis transmembrane conductance regulator (CFTR) folding and stability. J Biol Chem 287:21914-25
Bouchecareilh, M; Balch, W E (2012) Proteostasis, an emerging therapeutic paradigm for managing inflammatory airway stress disease. Curr Mol Med 12:815-26
Bouchecareilh, Marion; Hutt, Darren M; Szajner, Patricia et al. (2012) Histone deacetylase inhibitor (HDACi) suberoylanilide hydroxamic acid (SAHA)-mediated correction of ýý1-antitrypsin deficiency. J Biol Chem 287:38265-78

Showing the most recent 10 out of 83 publications